(19)
(11) EP 1 874 313 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
01.09.2010 Bulletin 2010/35

(45) Mention of the grant of the patent:
28.07.2010 Bulletin 2010/30

(21) Application number: 06744549.4

(22) Date of filing: 24.04.2006
(51) International Patent Classification (IPC): 
A61K 31/48(2006.01)
A61K 31/00(2006.01)
A61K 31/498(2006.01)
A61P 15/00(2006.01)
(86) International application number:
PCT/IB2006/000989
(87) International publication number:
WO 2006/117608 (09.11.2006 Gazette 2006/45)

(54)

TREATMENT OR PREVENTION OF OVARIAN HYPERSTIMULATION SYNDROME (OHSS) USING A DOPAMINE AGONIST

BEHANDLUNG ODER VORBEUGUNG DES OVARIELLEN ÜBERSTIMULATIONSSYNDROMS (OHSS) MIT EINEM DOPAMINAGONISTEN

TRAITEMENT OU PREVENTION DU SYNDROME D'HYPERSTIMULATION OVARIENNE (OHSS) AU MOYEN D'UN AGONISTE DE LA DOPAMINE


(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

(30) Priority: 29.04.2005 US 676165 P

(43) Date of publication of application:
09.01.2008 Bulletin 2008/02

(73) Proprietor: Ferring International Center S.A.
1162 Saint-Prex (CH)

(72) Inventors:
  • PELLICER-MARTINEZ, Antonio
    ES-46004 Valencia (ES)
  • ARCE, Joan-Carlos
    DK-2791 Dragor (DK)
  • SIMON-VALLES, Carlos
    ES-46110 Valencia (ES)
  • GOMEZ-GALLEGO, Raul
    Vallduixo, 12600 Castellón de la Plana (ES)

(74) Representative: Bates, Philip Ian 
Reddie & Grose 16 Theobalds Road
London WC1X 8PL
London WC1X 8PL (GB)


(56) References cited: : 
   
  • PAPALEO ENRICO ET AL: "Cabergoline influences ovarian stimulation in hyperprolactinaemic patients with polycystic ovary syndrome" HUMAN REPRODUCTION (OXFORD), vol. 16, no. 11, November 2001 (2001-11), pages 2263-2266, XP002393408 ISSN: 0268-1161
  • GOMEZ RAUL ET AL: "Tyroxine hydroxylase (TH) downregulation in hyperstimulated ovaries reveals the dopamine agonist Bromocriptine (Br2) as an effective and specific method to block increased vascular permeability (VP) in OHSS." FERTILITY AND STERILITY, vol. 80, no. Suppl. 3, September 2003 (2003-09), pages S43-S44, XP009070619 & 59TH ANNUAL MEETING OF THE AMERICAN SOCIETY FOR REPRODUCTIVE MEDICINE; SAN ANTONIO, TEXAS, USA; OCTOBER 11-15, 2003 ISSN: 0015-0282
  • MORRIS RANDY S ET AL: "Conservative management of ovarian hyperstimulation syndrome" JOURNAL OF REPRODUCTIVE MEDICINE, vol. 40, no. 10, 1995, pages 711-714, XP009070629 ISSN: 0024-7758
  • MANNO ET AL: "Cabergoline: a safe, easy, cheap, and effective drug for prevention/treatment of ovarian hyperstimulation syndrome?" EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, EXCERPTA MEDICA, AMSTERDAM,, NL, vol. 122, no. 1, 1 September 2005 (2005-09-01), pages 127-128, XP005067200 ISSN: 0301-2115
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).